424B5 1 file001.htm FORM 424B5

Filed Pursuant to Rule 424(b)(5)
Registration File No.: 333-121067

PRICING SUPPLEMENT No. 13
to Prospectus Supplement dated May 18, 2005
to Prospectus Supplement dated May 18, 2005
and Prospectus dated May 18, 2005

$10,720,000
LEHMAN BROTHERS HOLDINGS INC.
MEDIUM-TERM NOTES, SERIES H
0.25% Notes Due January 6, 2012
Performance Linked to the Common Stock of Amgen Inc. (AMGN)

Because these notes are part of a series of Lehman Brothers Holdings' debt
securities called Medium-Term Notes, Series H, this pricing supplement and the
accompanying prospectus supplement, dated May 18, 2005 (the "synthetic
convertible prospectus supplement") should also be read with the accompanying
prospectus supplement, dated May 18, 2005 (the "MTN prospectus supplement") and
the accompanying prospectus dated May 18, 2005 (the "base prospectus"). Terms
used here have the meanings given them in the synthetic convertible prospectus
supplement, the MTN prospectus supplement or the base prospectus, unless the
context requires otherwise.

o REFERENCE EQUITY: The common stock of Amgen Inc. Amgen Inc. is not involved
in this offering and has no obligation with respect to the notes.

o STATED MATURITY DATE: January 6, 2012, subject to postponement if the
valuation date is postponed.

o INTEREST RATE: 0.25% per annum.

o INTEREST PAYMENT DATES: January 6 and July 6 of each year, beginning on
July 6, 2006.

o INTEREST PAYMENT RECORD DATES: 15 calendar days prior to each interest
payment date.

o PRINCIPAL AMOUNT: $1,000 per note, and in the aggregate, $10,720,000.

o THRESHOLD VALUE: $87.6254, which represents 110.75% of $79.12, which is the
average execution price per share of common stock that an affiliate of
Lehman Brothers Holdings has paid to hedge Lehman Brothers Holdings'
obligations under the notes.

o EARLIEST REDEMPTION DATE: December 29, 2008.

o REDEMPTION NOTICE PERIOD: 30 calendar days.

o OPTIONAL REPURCHASE NOTICE PERIOD: Eight business days.

o DETERMINATION PERIOD: Three business days.

o MULTIPLIER: The initial multiplier for the shares of common stock of Amgen
Inc. is 1.0. The multiplier is subject to adjustment under various
circumstances, as described under the caption "Description of the
Notes--Adjustments to multipliers and to securities included in the
calculation of the settlement value" on page SS-16 of the synthetic
convertible prospectus supplement, including if Amgen Inc. pays a cash
dividend on its shares of common stock.

o STOCK SETTLEMENT: Yes, upon exercise by the holder of the repurchase option
and at the option of Lehman Brothers Holdings at maturity, all as described
under the caption "Description of the Notes--Stock settlement" on page SS-21
of the synthetic convertible prospectus supplement. Lehman Brothers Holdings
will provide the trustee with not less than 15 calendar days' prior written
notice if it elects the stock settlement option.

o LISTING: The notes will not be listed on any exchange.

Investing in the notes involves risks. Risk Factors begin on page SS-7 of
the synthetic convertible prospectus supplement.

Neither the Securities and Exchange Commission nor any state securities
commission has approved or disapproved of these securities or determined if this
pricing supplement, any accompanying prospectus supplement or any accompanying
prospectus is truthful or complete. Any representation to the contrary is a
criminal offense.

----------------------
Per Note Total
---------- ---------------
Public offering price............................... 100.00% $10,720,000
Underwriting discount............................... 0.25% $26,800
Proceeds to Lehman Brothers Holdings................ 99.75% $10,693,200

----------------------

Lehman Brothers Holdings has granted the underwriter an option to purchase,
within 13 days of the original issuance, up to an additional $1,608,000
aggregate principal amount of notes on the same terms and conditions set forth
above solely to cover over-allotments, if any.

The notes are expected to be ready for delivery in book-entry form only through
The Depository Trust Company on or about January 6, 2006.

----------------------

LEHMAN BROTHERS
December 29, 2005

EXAMPLES OF AMOUNT PAYABLE AT MATURITY OR UPON REDEMPTION OR REPURCHASE

Here are two examples of hypothetical alternative redemption amount
calculations. In each of these examples it is assumed that Amgen Inc. does not
pay any cash dividend on its shares of common stock during the term of the
notes.

EXAMPLE 1. ASSUMING THE SETTLEMENT VALUE IS $72.00:

Alternative redemption amount per $1,000 note =

$72.00
$1,000 x ---------- = $821.67
$87.6254

As a result, on the maturity date or upon redemption, you would receive $1,000,
plus accrued but unpaid interest, per $1,000 note because $1,000 is greater than
$821.67.

In the case of stock settlement in this example, you would receive, if you held
a $1,000 note, 13 shares of common stock of Amgen Inc. plus $64.00 in cash, plus
accrued but unpaid interest, at maturity, or 11 shares of common stock of Amgen
Inc. plus $29.67 in cash, plus accrued but unpaid interest, upon repurchase. To
the extent that you hold more than $1,000 aggregate principal amount of notes,
the calculations of cash payments in lieu of fractional shares would be made on
an aggregate, rather than on a per $1,000 note, basis. For example, if you held
$10,720,000 aggregate principal amount of notes, you would receive, in total,
148,888 shares of common stock of Amgen Inc. plus $64.00 in cash, plus accrued
but unpaid interest, at maturity, or 122,337 shares of common stock of Amgen
Inc. plus $38.40 in cash, plus accrued but unpaid interest, upon repurchase.

EXAMPLE 2. ASSUMING THE SETTLEMENT VALUE IS $108.00:

Alternative redemption amount per $1,000 note =

$108.00
$1,000 x ----------- = $1,232.51
$87.6254

As a result, on the maturity date or upon redemption, you would receive
$1,232.51, plus accrued but unpaid interest, per $1,000 note because $1,232.51
is greater than $1,000.

In the case of stock settlement in this example, you would receive, if you held
a $1,000 note, 11 shares of common stock of Amgen INC. plus $44.51 in cash, plus
accrued but unpaid interest, at maturity or upon repurchase. To the extent that
you hold more than $1,000 aggregate principal amount of notes, the calculations
of cash payments in lieu of fractional shares would be made on an aggregate,
rather than on a per $1,000 note, basis. For example, if you held $10,720,000
aggregate principal amount of notes, you would receive, in total, 122,338 shares
of common stock of Amgen Inc. plus $3.20 in cash, plus accrued but unpaid
interest, at maturity or upon repurchase.

To the extent the actual settlement value differs from the values assumed above
or that Amgen Inc. begins to pay cash dividends, the results indicated above
would be different.

PS-2

THE INDEX STOCK

AMGEN INC.

Lehman Brothers Holdings has obtained the following information regarding Amgen
Inc. from Amgen Inc.'s reports filed with the SEC.

Amgen Inc. is a global biotechnology company that discovers, develops,
manufactures and markets human therapeutics based on advances in cellular and
molecular biology.

Amgen Inc. focuses its research and development efforts on human therapeutics
delivered in the form of proteins, monoclonal antibodies and small molecules in
the areas of hematology, oncology, inflammation, metabolic and bone disorders
and neuroscience. Amgen Inc. has research facilities in the United States, and
has clinical development staff in the United States, Europe, Canada, Australia
and Japan. In addition to internal research and development efforts, Amgen Inc.
has acquired certain product and technology rights and has established research
and development collaborations.

Amgen Inc. operates commercial manufacturing facilities located in the United
States and Puerto Rico, and a packaging and distribution center in The
Netherlands. Amgen Inc. maintains a sales and marketing force in the United
States, Europe, Canada, Australia and New Zealand.

The index stock is registered under the Securities Exchange Act of 1934.
Companies with securities registered under that Act are required to file
periodically certain financial and other information specified by the SEC.
Information provided to or filed with the SEC can be inspected and copied at the
public reference facilities maintained by the SEC or through the SEC's website
described under "Where You Can Find More Information" on page 58 of the
accompanying base prospectus. In addition, information regarding the index stock
issuer may be obtained from other sources including, but not limited to, press
releases, newspaper articles and other publicly disseminated documents.

HISTORICAL INFORMATION ABOUT THE SHARES OF COMMON STOCK OF AMGEN INC.

The shares of common stock of Amgen Inc. are quoted on The NASDAQ Stock Market
under the symbol "AMGN".

The following table presents the high and low closing prices for the shares of
common stock of Amgen Inc., as reported on The NASDAQ Stock Market during each
fiscal quarter in 2002, 2003, 2004 and 2005 (through the date of this pricing
supplement), and the closing price at the end of each quarter in 2002, 2003,
2004 and 2005 (through the date of this pricing supplement).

The historical prices of the index stock are not indications of future
performance. Lehman Brothers Holdings cannot assure you that the prices of the
index stock will not fall below the threshold value or will increase enough so
that the alternative redemption amount will be greater than or equal to $1,000.
The historical prices below have been adjusted to reflect any stock splits or
reverse stock splits.

All information in the table that follows was obtained from Bloomberg L.P.,
without independent verification.

PS-3

HIGH LOW PERIOD END
-------- --------- ------------
2002
First Quarter........................ $62.48 $54.33 $59.68
Second Quarter....................... 61.39 37.80 41.88
Third Quarter........................ 48.54 31.07 41.70
Fourth Quarter....................... 51.75 43.66 48.34

2003
First Quarter ....................... $58.87 $48.88 $57.55
Second Quarter....................... 67.50 57.60 65.94
Third Quarter........................ 71.54 64.52 64.52
Fourth Quarter....................... 67.14 57.62 61.79

2004
First Quarter ....................... $66.23 $57.83 $58.15
Second Quarter....................... 60.43 52.82 54.57
Third Quarter........................ 59.98 53.23 56.81
Fourth Quarter....................... 64.76 52.70 64.15

2005
First Quarter ....................... $64.87 $57.98 $58.21
Second Quarter ...................... 63.18 57.20 60.46
Third Quarter........................ 86.17 60.86 79.67
Fourth Quarter (through the date of
this pricing supplement)........... 84.42 73.37 79.02

PS-4

HYPOTHETICAL RETURNS

The table below illustrates, for a range of hypothetical settlement values
calculated on the valuation date:

o the hypothetical alternative redemption amount per $1,000 note;

o the percentage change from the principal amount to the hypothetical
alternative redemption amount;

o the hypothetical total amount payable at stated maturity per $1,000 note
(without interest);

o the hypothetical total rate of return (without interest);

o the hypothetical annualized pre-tax rate of return (without interest);

o the hypothetical total rate of return (including interest); and

o the hypothetical annualized pre-tax rate of return (including interest).

PERCENTAGE HYPOTHETICAL
CHANGE OF TOTAL AMOUNT HYPOTHETICAL HYPOTHETICAL
HYPOTHETICAL PAYABLE AT ANNUALIZED ANNUALIZED
HYPOTHETICAL ALTERNATIVE STATED HYPOTHETICAL PRE-TAX HYPOTHETICAL PRE-TAX
HYPOTHETICAL ALTERNATIVE REDEMPTION MATURITY PER TOTAL RATE RATE OF TOTAL RATE RATE OF
SETTLEMENT REDEMPTION AMOUNT OVER $1,000 NOTE OF RETURN RETURN OF RETURN RETURN
LEVEL ON THE AMOUNT PER THE PRINCIPAL (WITHOUT (WITHOUT (WITHOUT (INCLUDING (INCLUDING
VALUATION DATE $1,000 NOTE AMOUNT INTEREST) INTEREST) INTEREST) INTEREST) INTEREST)
-------------- ------------ ------------- ------------ ------------ ------------ ------------ ------------

$ 20.00 $ 228.24 -77.18% $1,000.00 0.00% 0.00% 1.50% 0.25%
40.00 456.49 -54.35 1,000.00 0.00 0.00 1.50 0.25
60.00 684.73 -31.53 1,000.00 0.00 0.00 1.50 0.25
80.00 912.98 -8.70 1,000.00 0.00 0.00 1.50 0.25
87.6254 (1) 1,000.00 0.00 1,000.00 0.00 0.00 1.50 0.25
100.00 1,141.22 14.12 1,141.22 14.12 2.23 15.62 2.45
120.00 1,369.47 36.95 1,369.47 36.95 5.38 38.45 5.57
140.00 1,597.71 59.77 1,597.71 59.77 8.12 61.27 8.29
160.00 1,825.95 82.60 1,825.95 82.60 10.56 84.10 10.71

----------------------
(1) This figure reflects the threshold value.

For purposes of this table, it is assumed that Amgen Inc. does not pay any cash
dividend on its shares of common stock during the term of the notes.

The above figures are for purposes of illustration only. The actual amount
received by investors and the resulting total and pre-tax rates of return will
depend entirely on the actual settlement value determined by the calculation
agent. In particular, the actual settlement value could be lower or higher than
those reflected in the table.

The table above only provides hypothetical return information with regard to
notes held to maturity. It is not applicable in the case of notes repurchased or
redeemed prior to the stated maturity date.

You should compare the features of the notes to other available investments
before deciding to purchase the notes. Due to the uncertainty as to whether the
alternative redemption amount, at stated maturity or in connection with a
repurchase or redemption, will be greater than $1,000 per $1,000 note or whether
the notes will be redeemed prior to the stated maturity date, the return on
investment with respect to the notes may be higher or lower than the return
available on other securities issued by Lehman Brothers Holdings or by others
and available through Lehman Brothers Inc. You should reach an investment
decision only after carefully considering the suitability of the notes in light
of your particular circumstances.

PS-5

SUPPLEMENTAL UNITED STATES FEDERAL INCOME TAX CONSEQUENCES

Lehman Brothers Holdings is required to provide the comparable yield to you and,
solely for tax purposes, is also required to provide a projected payment
schedule that includes the actual interest payments on the notes and estimates
the amount and timing of contingent payments on the notes. Lehman Brothers
Holdings has determined that the comparable yield is an annual rate of 5.045%
compounded semi-annually. Based on the comparable yield, the projected payment
schedule per $1,000 note is $1.25 semi-annually and $1,332.42 due at maturity.
Lehman Brothers Holdings agrees and, by purchasing a note, you agree, for United
States federal income tax purposes, to be bound by Lehman Brothers Holdings'
determination of the comparable yield and projected payment schedule. As a
consequence, for United States federal income tax purposes, you must use the
comparable yield determined by Lehman Brothers Holdings and the projected
payments set forth in the projected payment schedule prepared by Lehman Brothers
Holdings in determining your interest accruals, and the adjustments thereto, in
respect of the notes.

Because there is no statutory, judicial, or administrative authority directly
addressing the characterization of notes with terms such as the notes for United
States federal income tax purposes, it is possible that the Internal Revenue
Service could assert characterizations other than those described in the
accompanying synthetic convertible prospectus supplement that could affect the
timing, amount and character of income, gain, loss or deduction. You should
consult your own tax advisors concerning the federal income tax consequences of
the notes in light of your particular situation. See "United States Federal
Income Tax Consequences" in the accompanying synthetic convertible prospectus
supplement.

PS-6

SUPPLEMENTAL PLAN OF DISTRIBUTION

Lehman Brothers Holdings has agreed to sell to Lehman Brothers Inc. and Lehman
Brothers Inc. has agreed to purchase, all of the notes at the price indicated on
the cover of this pricing supplement.

Lehman Brothers Holdings has agreed to indemnify Lehman Brothers Inc. against
liabilities, including liabilities under the Securities Act of 1933, as amended,
or to contribute to payments that Lehman Brothers Inc. may be required to make
relating to these liabilities as described in the MTN prospectus supplement and
the base prospectus.

Lehman Brothers Inc. will offer the notes initially at a public offering price
equal to the issue price set forth on the cover of this pricing supplement.
After the initial public offering, the public offering price may from time to
time be varied by Lehman Brothers Inc.

Lehman Brothers Holdings has granted to Lehman Brothers Inc. an option to
purchase, at any time within 13 days of the original issuance of the notes, up
to $1,608,000 additional aggregate principal amount of notes solely to cover
over-allotments. To the extent that the option is exercised, Lehman Brothers
Inc. will be committed, subject to certain conditions, to purchase the
additional notes. If this option is exercised in full, the total public offering
price, the underwriting discount and proceeds to Lehman Brothers Holdings would
be $12,328,000, $30,820 and $12,297,180, respectively.

Lehman Brothers Holdings expects to deliver the notes against payment on or
about January 6, 2006, which is the fifth business day following the date of
this pricing supplement.

Under Rule 15c6-1 of the Exchange Act, trades in the secondary market generally
are required to settle in three business days, unless the parties to any such
trade expressly agree otherwise. Accordingly, if any purchaser wishes to trade
the notes on the date of this pricing supplement, it will be required, by virtue
of the fact that the notes initially will settle on the fifth business day
following the date of this pricing supplement, to specify an alternate
settlement cycle at the time of any such trade to prevent a failed settlement.

An affiliate of Lehman Brothers Holdings has entered into a swap transaction in
connection with the notes and has received customary compensation for that
transaction.

PS-7

$10,720,000

LEHMAN BROTHERS HOLDINGS INC.
MEDIUM-TERM NOTES, SERIES H

0.25% NOTES DUE JANUARY 6, 2012
PERFORMANCE LINKED TO THE
COMMON STOCK OF AMGEN INC. (AMGN)

----------------------

PRICING SUPPLEMENT
DECEMBER 29, 2005

(INCLUDING PROSPECTUS SUPPLEMENT
DATED MAY 18, 2005,

PROSPECTUS SUPPLEMENT
DATED MAY 18, 2005 AND

PROSPECTUS
DATED MAY 18, 2005)

----------------------

LEHMAN BROTHERS